Bernardo Goulart, M.D., M.S.

Bernardo Goulart M.D., M.S.
FACULTY MEMBER

Bernardo Goulart, M.D., M.S.

Assistant Professor
Clinical Research Division, Fred Hutch

Joint Assistant Professor
Public Health Sciences Division, Fred Hutch

Joint Assistant Professor
Hutchinson Institute for Cancer Outcomes Research (HICOR), Fred Hutch

Fax: 206.667.5977
Mail Stop: K2-231

Dr. Bernardo Goulart is a medical oncologist and outcomes researcher who investigates the impact of various cancer treatment practices that matter to patients and society, such as survival, hospitalizations and direct medical costs. In both his oncology practice and his research, he specializes in head and neck and thoracic cancers, particularly non-small cell lung cancer, malignant pleural mesothelioma and thymic tumors. In his research, he designs and conducts studies that assess the quality and cost-effectiveness of cancer treatments currently being delivered nationwide and has a strong interest in finding solutions to the financial toxicity that plagues many cancer patients and their families. Areas of research interest include the costs and benefits of low-dose computed tomography, or CT, screenings; precision oncology/personalized medicine; and the human responses to pathological processes, especially the biology of cancer.

Other Appointments & Affiliations

Associate Professor
University of Washington School of Medicine

Attending Physician
Seattle Cancer Care Alliance

Education

Federal University of Rio de Janeiro, M.D., 1997

School of Pharmacy, University of Washington, M.S. (Master in Science) in the field of Pharmaceutical

Outcomes Research and Pharmacoeconomics – Pharmaceutical Outcomes Research and Policy Program (PORPP), 2010

Research Interests

As an outcomes researcher, I analyze large regional and national databases to investigate the impact of different treatment practices on outcomes that matter to patients and society, including survival, hospitalizations, and direct medical costs, with a focus on thoracic cancers.

Clinical Expertise

Thoracic cancers, particularly non-small cell lung cancer, malignant pleural mesothelioma, and thymic tumors.

Current Studies

National Cancer Institute (NCI) 12/31/2014-12/31/2017
5P30 CA015704-39 (PI: Gilliland)
CCSG Young Investigator Award, Fred Hutchinson Cancer Research Center

This proposal seeks to expand the knowledge on the use of precision oncology for non-small cell lung cancer (NSCLC) at the population level by validating a method for ascertainment of EGFR and ALK testing in SEER registries and by supporting the development of a patient cohort selected by positive EGFR and AKL test results with patient-level survival, hospitalization, and claims data from multiple insurance claims.
Role: Principal Investigator

Personalized Medicine Coalition (PMC) 07/01/2016 – 12/31/2017
Number: TBD (PI: Ramsey)
Clinical and Economic Value of Next Generation Sequencing-Based Diagnostic Testing in Cancer Care.

This project will employ decision analytic models and a value-of-information approach to determine: (1) the cost-effectiveness of the use of next generation sequencing genetic testing as a guide for treatment choices in stage IV non-small cell lung cancer and melanoma; (2) the value of future research in mitigating current uncertainty regarding the use of next generation sequencing.
Role: Co-investigator.

Gregory Fund Foundation 04/01/12 – 12/31/2015
(PI: Goulart)
Outcomes and Costs of Low-Dose Computed Tomography for Early Detection of Lung Cancer: a Pilot Study

The goal of this study is to establish feasibility of a prospective registry of patients referred for lung cancer screening with Low-Dose Computed Tomography at the Seattle Cancer Care Alliance that includes healthcare resource utilization, medical costs, screening test performance, QoL, and complications from screening.
Role: Principal Investigator

National Cancer Institute (NCI) 9/18/2015 – 9/17/2016
HHSN26100007 (PI: Goulart)
Assessing Molecular Profiling in Non-Small Cell Lung Cancer at the Population Level: A Validation Study of Natural Language Processing Algorithms for SEER

This project proposes to develop Natural Language Processing (NLP) algorithms to ascertain use, results, and techniques employed for EGFR and ALK testing, respectively, from SEER electronic pathology reports of stage IV non-squamous NSCLC registry cases.
Role: Co-Principal Investigator

National Cancer Institute (NCI) 12/31/2014-12/31/2017
5P30 CA015704-39 (PI: Gilliland)
CCSG Young Investigator Award, Fred Hutchinson Cancer Research Center
Real-World Impact of Target Therapies for EGFR and ALK Positive Advanced Non-Small Cell Lung Cancer (NSCLC): A Novel Population-based Retrospective Cohort Study

An extension of the NCI HHSN26100007 validation study for ascertainment of EGFR and ALK test results from SEER pathology reports, this research project involves the development of an unique retrospective cohort of EGFR and ALK positive stage IV non-small cell lung cancer patients whose records from the Fred Hutchinson Cancer Surveillance System (CSS) are linked to longitudinal outpatient, inpatient, and pharmacy claims. This cohort leverages longitudinal data on the care delivered to molecularly selected patient subgroups and the impact of different patterns of use of target therapies on survival, hospitalizations, and direct medical costs.

 

Dr. Goulart in the News

Natural language processing as a research aid

Science Spotlight - June 17, 2019

Artificial intelligence and cancer

Hutch News - May 06, 2019

7 lung cancer misconceptions

Hutch News - November 15, 2018

The lung cancer blame game

Hutch News - November 21, 2017

A model for progress in lung cancer survival

Science Spotlight - April 17, 2017

For the Media

The Media Relations team at Fred Hutch is available to assist members of the news media who would like to arrange interviews with faculty.

Email media@fredhutch.org or call 206.667.2210.